Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | December 20, 2024 | December 23, 2024 |
| MERIDIAN BIOSCIENCE INCVIVO · Entity 117499 | Exec VP & CFO | December 15, 2021 | December 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InMed Pharmaceuticals Inc.
Report date December 20, 2024 · Filed December 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2029-12-19 | Direct | 975 |
Reported balance
After 2024-12-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-20 · Grant · Acquired 550 · Balance 975 F1: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner. F2: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner.
F2: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split.
MERIDIAN BIOSCIENCE INC
Report date December 15, 2021 · Filed December 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,929 |
Reported balance
After 2021-12-15 transaction · row 1
1 source rowRow 1 · 2021-12-15 · Tax withholding · Disposed 1,985 · Balance 60,929 F1: Represent restricted stock units withheld by the Company under the net share settlement method to cover certain taxes due related to retirement eligibility, as follows: (i) 487 granted November 4, 2021; and (ii) 1,498 granted November 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent restricted stock units withheld by the Company under the net share settlement method to cover certain taxes due related to retirement eligibility, as follows: (i) 487 granted November 4, 2021; and (ii) 1,498 granted November 15, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2024 Filed Dec 23, 2024 09:18 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111548 · ownership.xml · derivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975 Underlying: Common shares · 550 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner. F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
| December 23, 2023 Filed Dec 26, 2023 13:05 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,100 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098488 · ownership.xml · derivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common shares · 7,100 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 16:50 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 840 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080962 · ownership.xml · derivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common shares · 840 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:24 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001213900-22-028300 · ownership.xml · derivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Shares · 14,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The options were granted on May 17, 2022 and will vest monthly, in arrears, as follows: (i) 390 stock options will vest on the 17th day of each month for 35 months, and (ii) 350 stock options will vest on May 17, 2025 (the three year anniversary of Grant date). Read SEC document |
| December 15, 2021 Filed Dec 22, 2021 08:17 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 1,985 | $17.92 | $35,571.20 |
DisclosureSEC source: 0001127602-21-031730 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,929 F1 · shares: Represent restricted stock units withheld by the Company under the net share settlement method to cover certain taxes due related to retirement eligibility, as follows: (i) 487 granted November 4, 2021; and (ii) 1,498 granted November 15, 2021. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 15:58 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 32,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-029298 · form4.xml · nonDerivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,721 F2 · price: Restricted share units granted pursuant to 2021 Omnibus Award Plan scheduled to vest as follows: (i) 1,200 on September 16, 2022; (ii) 20,534 on November 15, 2022; and (iii) 10,823 on November 15, 2023. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 15:58 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | OtherCommon Stock | 32,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-029298 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,164 F1 · price: Restricted share units granted pursuant to 2012 Stock Incentive Plan rescinded by the Issuer. Read SEC document |
| November 15, 2021 Filed Dec 16, 2021 16:38 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 3,807 | $20.16 | $76,749.12 |
DisclosureSEC source: 0001127602-21-031110 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,914 F1 · shares: Represent restricted stock units withheld by the Company under the net share settlement method to cover certain taxes due upon vesting of grants, as follows: (i) 1,523 granted November 8, 2017; and (ii) 2,284 granted November 15, 2018. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:09 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 11,669 | $0.00 Strike: $18.88 | $0.00 |
DisclosureSEC source: 0001127602-21-028575 · form4.xml · derivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,669 Underlying: Common Stock · 11,669 shares Expires 2031-11-04 F2 · derivative.exercise_date: These non-qualified options are awarded under the 2021 Omnibus Award Plan and vest as follows: (i) 25% of the options awarded vest on November 4, 2022; and (ii) the remaining 75% of the options awarded vest pro rata each month from November 4, 2022 through November 4, 2025. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:09 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 10,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028575 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,721 F1 · shares: These restricted stock units are awarded under the 2021 Omnibus Award Plan and vest in four equal installments from the date of grant (i.e., vest 25% per year until fully vested on November 4, 2025). Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 13:26 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $19.56 | $0.00 |
DisclosureSEC source: 0001127602-21-004586 · form4.xml · derivative · entry 3 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2026-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 17, 2020. F3 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan and vested in four equal installments from the date of grant and were fully vested on March 24, 2020. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 13:26 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 6,254 | $30.00 | $187,620.00 |
DisclosureSEC source: 0001127602-21-004586 · form4.xml · nonDerivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,128 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 17, 2020. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 13:26 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 3,750 | $19.56 | $73,350.00 |
DisclosureSEC source: 0001127602-21-004586 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 10:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $19.56 | $0.00 |
DisclosureSEC source: 0001127602-21-004269 · form4.xml · derivative · entry 3 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 11,250 shares Expires 2026-03-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 17, 2020. F4 · derivative.exercise_date: These non-qualified options were awarded under the 2012 Stock Incentive Plan and vested in four equal installments from the date of grant and were fully vested on March 24, 2020. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 10:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | SaleCommon Stock | 14,250 | $26.61 | $379,125.53 |
DisclosureSEC source: 0001127602-21-004269 · form4.xml · nonDerivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,632 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective September 17, 2020. F2 · price: Prices range from $25.00 per share to $29.00 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 10:21 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 11,250 | $19.56 | $220,050.00 |
DisclosureSEC source: 0001127602-21-004269 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Dec 21, 2020 14:22 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 1,991 | $17.11 | $34,059.04 |
DisclosureSEC source: 0001127602-20-032093 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,632 Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 13:28 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 12,107 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001127602-20-028457 · form4.xml · derivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,107 Underlying: Common Stock · 12,107 shares Expires 2030-11-05 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on 11/15/2023. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 13:28 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 10,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028457 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,623 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on 11/15/2023. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 13:52 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001127602-20-020774 · form4.xml · derivative · entry 3 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2020-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These non-qualified options were awarded under the 2004 Equity Compensation Plan and are fully vested and exercisable. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 13:52 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 1,337 | $23.29 | $31,138.73 |
DisclosureSEC source: 0001127602-20-020774 · form4.xml · nonDerivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,800 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 13:52 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Exercise / conversionCommon Stock | 1,500 | $19.71 | $29,565.00 |
DisclosureSEC source: 0001127602-20-020774 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 13:47 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 1,000 | $6.96 | $6,955.00 |
DisclosureSEC source: 0001127602-20-010224 · form4.xml · nonDerivative · entry 2 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,637 Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 13:47 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | PurchaseCommon Stock | 1,000 | $6.98 | $6,981.00 |
DisclosureSEC source: 0001127602-20-010224 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,637 Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 14:12 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | Tax withholdingCommon Stock | 1,968 | $8.56 | $16,846.08 |
DisclosureSEC source: 0001127602-19-033153 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,637 Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 13:58 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 20,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031602 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Exec VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,605 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest in full (100%) on November 15, 2022. Read SEC document |
| September 16, 2019 Filed Sep 23, 2019 14:50 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028923 · form4.xml · nonDerivative · entry 1 Baldasare Bryan T · CIK 0001761920 · Interim CFO & Chief Acctg Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,071 F1 · shares: These restricted stock units were granted under the 2012 Stock Incentive Plan in connection with the Company's acquisition of GenePOC Inc. and vest in full (i.e., 100%) on September 16, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.